Fusion Pharmaceuticals Inc.
FUSNDelisted Jun 5, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001805890
Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:23 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $94.9M (4588.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2024 | Mar 16, 2023 | Mar 17, 2022 | Mar 25, 2021 |
| Revenue | $2.07M | $1.46M | $1.44M | – |
| Operating expenses | $101.3M | $89.5M | $83.5M | $37.9M |
| Research and development | $70.1M | $58.9M | $56.4M | $17.2M |
| Selling, general and administrative | $31.2M | $30.6M | $27.1M | $20.7M |
| Operating income | -$99.2M | -$88.0M | -$82.0M | -$37.9M |
| Income tax | $787.0K | -$1.84M | -$118.0K | $2.61M |
| Net income | -$94.9M | -$87.6M | -$81.0M | -$78.3M |
| EPS, basic | $-1.45 | $-2.00 | – | – |
| EPS, diluted | $-1.45 | $-2.00 | – | – |
| Weighted shares, basic | 65.6M | 43.7M | – | – |
| Weighted shares, diluted | 65.6M | 43.7M | – | – |
| Margins and growth | ||||
| Operating margin | -4798.5% | -6025.6% | -5695.5% | – |
| Net margin | -4588.8% | -5996.7% | -5628.3% | – |
| Revenue growth, year over year | +41.5% | +1.5% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2024 | Mar 16, 2023 | Mar 17, 2022 | Mar 25, 2021 |
| Cash and equivalents | $61.5M | $43.9M | $52.9M | $90.5M |
| Short-term investments | $172.2M | $127.0M | $147.9M | $131.9M |
| Accounts receivable | $7.00K | $61.0K | $357.0K | – |
| Total current assets | $243.4M | $179.0M | $211.8M | $228.2M |
| Property, plant and equipment | $5.30M | $4.63M | $2.97M | $1.97M |
| Total assets | $285.8M | $219.1M | $252.3M | $310.7M |
| Accounts payable | $1.86M | $2.69M | $2.19M | $3.40M |
| Short-term debt | $35.0M | $35.0M | – | – |
| Total current liabilities | $16.2M | $15.1M | $12.5M | $11.9M |
| Long-term debt | $34.8M | $34.2M | – | – |
| Total liabilities | $63.4M | $56.8M | $20.8M | $16.2M |
| Shareholders' equity | $222.5M | $162.2M | $231.5M | $294.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2024 | Mar 16, 2023 | Mar 17, 2022 | Mar 25, 2021 |
| Operating cash flow | -$81.8M | -$73.3M | -$75.7M | -$29.8M |
| Capital expenditures | $3.89M | $2.14M | $1.49M | $1.12M |
| Free cash flow | -$85.7M | -$75.4M | -$77.2M | -$30.9M |
| Depreciation and amortization | $1.34M | $909.0K | $634.0K | $482.0K |
| Stock-based compensation | $12.4M | $10.8M | $8.60M | $3.37M |
| Investing cash flow | -$42.8M | $23.1M | $37.8M | -$210.5M |
| Financing cash flow | $142.0M | $40.7M | $347.0K | $265.5M |
| Net change in cash | $17.4M | -$9.46M | -$37.6M | – |
| Ratio | ||||
| Stock-based compensation, % of revenue | 601.7% | 742.2% | 597.4% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 29, 2024 | 85.1M | +33.2% | SEC |
| Apr 3, 2024 | 84.9M | +32.9% | SEC |
| Mar 11, 2024 | 84.7M | +34.0% | SEC |
| Oct 27, 2023 | 72.4M | +61.8% | SEC |
| Jul 28, 2023 | 69.0M | +59.0% | SEC |
| May 2, 2023 | 63.8M | +47.3% | SEC |
| Mar 6, 2023 | 63.2M | +45.8% | SEC |
| Oct 28, 2022 | 44.8M | +3.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.